生产企业：PeproMene Bio, Inc.
PMB-CT01 is a first-in-class B-cell activating factor receptor (BAFF-R)-targeted autologous CAR T-cell therapy developed by PeproMene Bio, Inc. It is being evaluated in ongoing Phase 1 trials for relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL) and relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL).
PMB-CT01 is a first-in-class B-cell activating factor receptor (BAFF-R)-targeted autologous CAR T-cell therapy developed by PeproMene Bio, Inc. It is being evaluated in ongoing Phase 1 trials for relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL) and relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL).
